Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Wins Exon 51 Composition Patent Rights Over BioMarin

Sep 22 2016

• By Brenda Sandburg

Related Content

BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Jan 14 2016

Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

Sep 21 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Related Companies

Sarepta Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

Policy Legal Issues Intellectual Property BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window